Warning
All listed doses assume Adult patient (>18 years old) and normal renal/hepatic function
Children / <18 years old
Refer to: BNFC

Renal / hepatic impairment
Refer to: BNF BNFC , and Renal Drug Database.

Antimicrobial agents reported as "I" (i.e. Susceptible, increased exposure (increased dose))
These agents should not be avoided, but should be given at an increased dose. They remain appropriate treatment options when given at the correct dose:
Dosing for isolates reported as I: Adults
Dosing for isolates reported as I: Paediatric

Drug interactions, side effects and safety considerations
An abbreviated list of important considerations can be found within User guide - General, Drug interactions, side effects and safety considerations.
For full list of warnings, drug interactions & side effects please refer to drug-specific sections of the or .

Antibiotic  Adult Oral Dose
Normal hepatic/renal function
Aciclovir
   
800mg five times daily
Amoxicillin
   
500mg three times daily 
Cefalexin
   
500mg twice daily
Ciprofloxacin
500mg twice daily

MHRA safety advice
• D&G Quinolone Poster
• PIL must be provided

Clarithromycin
   
500mg twice daily 
Co-amoxiclav
   
625mg three times daily 
Co-trimoxazole
   
960mg twice daily 
Doxycycline
   
200mg on day one then 100mg daily
Severe / osteomyelitis: 200mg on day one then 100mg twice daily 
Flucloxacillin
   
1g four times daily
Mild: 500mg four times daily
Metronidazole
   
400mg three times daily 
Nitrofurantoin
   
50mg four times daily
If unavailable: 100mg modified release twice daily

eGFR <30ml/min: Contraindicated
eGFR 30-44ml/min: Caution; short term use only

Ofloxacin
   
200mg twice daily

MHRA safety advice
• D&G Quinolone Poster
• PIL must be provided

Penicillin V / Phenoxymethylpenicillin
   
500mg four times daily
Pivmecillinam
   
400mg initial dose then 200mg three times daily.
If known ESBL/AmpC: 400mg three times daily
Terbinafine
   
250mg daily
Trimethoprim
   
200mg twice daily

 

Editorial Information

Last reviewed: 31/07/2024

Next review date: 31/07/2027

Version: V1.0

Approved By: AMT (23.07.24) and ADTC (31.07.24)

Reviewer name(s): Jon van Aartsen (consultant microbiologist), Claire Mitchell (pharmacist).